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Pulmonary hypertension (PH) can present at any age from the neonatal period to adulthood.
Pediatric PH is similar to adults but differentiates itself as in a growing child the lungs are still
developing (1). It is a hemodynamic condition defined by an increased pulmonary artery mean
pressure above or equal to 25mmHg (1). This can be associated with multiple clinical conditions
forming different etiological groups with specific and diverse pathological and pathobiological
characteristics (1). When implying an abnormal reduction of small pulmonary arteries section
due to endothelial dysfunction, medial proliferation, and adventitial fibrosis, the disease is called
pulmonary arterial hypertension (PAH). PAH induces typically a severe and devastating PH that
leads to right heart failure and premature death.
Until recently, the vast majority of studies published on PH were in the adult population but, as
highlighted by the series of manuscript published in this issue of frontiers in pediatrics, awareness
about pediatric PH is growing. In this line, a specific subgroup was dedicated to pediatrics at the last
world symposium on PH with the publication of an excellent summary (1). Manuscripts not only
on clinical research but also on basic science further highlight the interest in pediatric PH.
Epidemiologic data, mainly sourced from national and international registries, have recently
been published, but the content of these registries varies depending on the center involved and
the inclusion criteria (2). Indeed, most of the registries, including centers from developed coun-
tries, do not report children with PAH associated with HIV, in contrast to reports coming from
developing countries (3). This may be due to the absence of this problem in developed countries
in association with aggressive antiretroviral therapies or the absence of screening. L’Huillier et al.
report the data from a Swiss cohort of patients with HIV (4). No patient presented with PH, but
screening of PH was not systematically performed. This must be kept in mind when analyzing
epidemiologic data.
In pediatrics, there is a need and a constant search for non-invasive assessments of PH, mainly
because right heart catheterization, whenever it is still considered as the gold standard for hemody-
namic evaluation and PH diagnosis is associated with potential risk in this particular population.
So, the development of non-invasive tools for hemodynamic evaluation is not only desirable but
mandatory in pediatrics. To this purpose, echocardiography gives invaluable information during
the follow-up. Jone and Ivy did an excellent review of the current knowledge application of this
approach in pediatric PH (5) and offer a basis for the remaining work dedicated to validation of
most of the discussed parameters. Similarly, Day et al. reported their experience with the use of
oxygen and sildenafil for assessment of pulmonary vascular reactivity in children (6). The response to
vasoreactivity testing is crucial for orientation of treatment strategy as responders can be treatedwith
calcium channel blockers with an excellent survival rate. This was clearly demonstrated in adults (7)
butwe still have towork to define a similar approach in children.Here, amajor question still remains:
what is the definition of a responder? The manuscript of Day et al. brings some more information
with regards to vasoreactivity assessments in pediatric PH.
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Still in the field of non-invasive assessment and potential mark-
ers of disease, Latus et al. reported their experience with the anal-
ysis of heart rate variability (HRV) showing that this parameter
may be altered in pediatric patients with PH (8). HRVmay indeed
be related to disease severity and serve as an additional marker for
PH evaluation.
Although there is still no cure for PAH, quality of life and
survival have been improved significantly with specific drug ther-
apies (9). Nevertheless, management of pediatric PAH remains
challenging and depends mainly on results from adult clinical
trials, a few specific pediatric studies and pediatric experts’ recom-
mendations. Any additional report of the use of targeted therapies
in children is of interest. Siehr et al. reported their experience
with the use of sildenafil and concentrated on its potential side
effects (10). One must remember that a question was raised on
the use of sildenafil in children as the STARTS study reported an
increased risk of death using high doses (11, 12). This led to a
warning from the FDA and the approval of the medium dose by
the European Medical Authorities. Even, if Siehr et al. reported
no new side effects, they mention that the incidence of vascular,
gastrointestinal, and neurologic side effects in pediatric patients
on sildenafil therapy was 30%. Side effects were more common
in patients on combination therapy with an endothelin receptor
antagonist and/or a prostacyclin than in patients on sildenafil
monotherapy.
Prior to the development of new therapeutic pathways, recog-
nition of all pathobiological pathways involved in the develop-
ment of pulmonary vascular disease are needed. Van loon et al.
(13) reported their experience with erythropoietin (EPO) (10).
In experimental PAH, EPO treatment restored the number of
circulating endothelial progenitor cells (EPCs) to control level,
improved pulmonary vascular remodeling, and showed impor-
tant interplay with heme oxygenase (HO) activity. Inhibition of
increased HO activity in PAH rats exacerbated progression of
pulmonary vascular remodeling, despite the presence of restored
number of circulating EPCs. It may be that both EPO-induced
HO and EPCs are promising targets to improve the pulmonary
vasculature in PAH.
Different specific issues related to pediatric PAH have been
reported and highlight the need to continue active research in
this field. It is of paramount importance to better understand
the pathobiology of the disease, its behavior and discover new
treatment pathway in order to finally curing this devastating
disease.
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